-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

What’s New in the Diagnosis and Pathophysiology of Thrombotic Thrombocytopenic Purpura

Program: Education Program
Session: Update on Diagnosis and Management of Thrombotic Thrombocytopenic Purpura
Saturday, December 5, 2015, 2:00 PM-3:30 PM
Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)
Monday, December 7, 2015, 10:30 AM-12:00 PM
Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

J. Evan Sadler, MD, PhD

Washington University Medical School, Saint Louis, MO

Disclosures: Sadler: Baxter HealthCare: Membership on an entity’s Board of Directors or advisory committees ; Band Therapeutics: Consultancy ; BioMarin: Consultancy ; XO1 Limited: Membership on an entity’s Board of Directors or advisory committees . Off Label Use: Rituximab for thrombotic thrombocytopenic purpura.

See more of: Update on Diagnosis and Management of Thrombotic Thrombocytopenic Purpura
See more of: Education Program
Previous Presentation | Next Presentation >>